Dr. Kazmi Discusses Olanzapine for Breakthrough CINV


Dr. Shayma Kazmi, from Cancer Treatment Centers of America, on Olanzapine for Breakthrough Chemotherapy-Induced Nausea and Vomiting

Shayma Kazmi, MD, medical oncologist, Cancer Treatment Centers of America, Eastern Regional Medical Center, discusses olanzapine for breakthrough chemotherapy-induced nausea and vomiting.

A Phase III trial to be presented at ASCO found that in cancer patients with chemotherapy-induced nausea and vomiting (CINV) that does not respond to conventional treatments, olanzapine was effective in controlling side effects.

Kazmi says that, in the past, antipsychotic medications such as haldol and haloperidol were used to control CINV. However, those medications tended to have undesirable side effects, with fatigue being the most common.

Olanzapine is a newer antipsychotic medication used to help control CINV. The drug affects the nausea center in the brain as a side effect, but how it does so is unknown. Olanzapine also helps patients with sleep, so it can be used in patients with severe insomnia as well.


View more from the 2012 ASCO Conference

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Coral Olazagasti, MD
Samuel Rosner, MD
Balazs Halmos, MD